Xeris Pharmaceuticals Inc (XERS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Sales | 48,065 | 40,638 | 44,390 | 48,320 | 38,008 |
| Cost of Goods | 7,790 | 5,971 | 7,570 | 8,201 | 7,555 |
| Gross Profit | 40,275 | 34,667 | 36,820 | 40,119 | 30,453 |
| Operating Expenses | 49,252 | 49,883 | 47,231 | 45,233 | 46,987 |
| Operating Income | -8,187 | -14,245 | -9,841 | -4,913 | -15,979 |
| Interest Expense | 7,964 | 7,032 | 7,018 | 6,847 | 6,528 |
| Other Income | 1,895 | 2,604 | 3,233 | -767 | 1,990 |
| Pre-tax Income | -14,256 | -18,673 | -13,626 | -12,527 | -20,517 |
| Income Tax | 749 | 307 | -236 | -338 | -675 |
| Net Income Continuous | -15,005 | -18,980 | -13,390 | -12,189 | -19,842 |
| Net Income | $-15,005 | $-18,980 | $-13,390 | $-12,189 | $-19,842 |
| EPS Basic Total Ops | -0.10 | -0.14 | -0.10 | -0.09 | -0.14 |
| EPS Basic Continuous Ops | -0.10 | -0.14 | -0.10 | -0.09 | -0.14 |
| EPS Diluted Total Ops | -0.10 | -0.14 | -0.10 | -0.09 | -0.14 |
| EPS Diluted Continuous Ops | -0.10 | -0.14 | -0.10 | -0.09 | -0.14 |
| EPS Diluted Before Non-Recurring Items | -0.10 | -0.14 | -0.10 | N/A | N/A |
| EBITDA(a) | $-4,708 | $-10,458 | $-6,055 | $-173 | $-12,487 |